Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.32 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.32 |
| ▸ | TK1 | P04183 | 1/20 | 0.32 |
| ▸ | POLA1 | P09884 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PAX3 | P23760 | 1/20 | 0.31 |
| ▸ | FOXO1 | Q12778 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25387611 | 0.76 | KDM4E (0.41) | KDM4ETAS1R3TAS1R1TK1POLA1 | |
| SCHEMBL6397988 | 0.75 | KDM4E (0.46) | KDM4ETAS1R3TAS1R1POLA1MEN1 | |
| SCHEMBL7211289 | 0.75 | KDM4E (0.43) | KDM4ETAS1R3TAS1R1TK1POLA1 | |
| SCHEMBL7064863 | 0.75 | KDM4E (0.39) | KDM4ETAS1R3TAS1R1TK1MEN1 | |
| SCHEMBL8896757 | 0.74 | KDM4E (0.47) | KDM4ETAS1R3TAS1R1TK1POLA1 | |
| SCHEMBL9548623 | 0.74 | ADORA3 (0.40) | TK1MEN1TSHRKMT2A | |
| SCHEMBL11051437 | 0.73 | KDM4E (0.45) | KDM4ETAS1R3TAS1R1TK1POLA1 | |
| SCHEMBL5223432 | 0.72 | RNASE1 (0.41) | TK1 | |
| SCHEMBL27930721 | 0.72 | KDM4E (0.45) | KDM4ETAS1R3TAS1R1TK1POLA1 | |
| SCHEMBL1612199 | 0.72 | KDM4E (0.43) | KDM4ETAS1R3TAS1R1MEN1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070292875-A1 | Human RNase H1 oligonucleotide compositions thereof | ISIS PHARMACEUTICALS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070123702-A1 | Oligonucleotdies having A-DNA form and B-DNA form conformational geometry | MANOHARAN MUTHIAH | 2007-05-31 | — | — | US | disclosed |
| US-7119184-B2 | Oligonucleotides having A-DNA form and B-DNA form conformational geometry | ISIS PHARMACEUTICALS, INC. (US) | 2006-10-10 | — | — | US | disclosed |
| EP-1222309-B1 | HUMAN RNASE H AND OLIGONUCLEOTIDE COMPOSITIONS THEREOF | ISIS PHARMACEUTICALS INC (US) | 2005-12-07 | — | — | EP | disclosed |
| US-6811975-B2 | MIMIC OR MODULATE ACTIVITY OF WILD-TYPE NUCLEIC ACIDS THEREBY AFFECTING PROTEIN PRODUCTION OR ACTIVITY | ISIS PHARMACEUTICALS, INC. | 2004-11-02 | — | — | US | disclosed |
| US-20040102618-A1 | Human RNase H1 and oligonucleotide compositions thereof | ISIS PHARMACEUTICALS, INC. | 2004-05-27 | — | — | US | disclosed |
| US-6737520-B2 | FOR USE AS SUBSTRATE FOR RIBONUCLEASE AND CONTROLLING BINDING AFFINITY/NUCLEASE RESISTANCE | ISIS PHARMACEUTICALS, INC. | 2004-05-18 | — | — | US | disclosed |
| US-20030105311-A1 | Oligonucleotides having A-DNA form and B-DNA form conformational geometry | ISIS PHARMACEUTICALS, INC. | 2003-06-05 | — | — | US | disclosed |
| US-20030096979-A1 | Oligonucleotides having A-DNA form and B-DNA form conformational geometry | ISIS PHARMACEUTICALS, INC. | 2003-05-22 | — | — | US | disclosed |
| US-6369209-B1 | AFFINITY AND NUCLEASE RESISTANCE WHILE CONCURRENTLY SERVING AS SUBSTRATES FOR RNASE H WHEN BOUND TO A TARGET RNA STRAND | ISIS PHARMACEUTICALS, INC. | 2002-04-09 | — | — | US | disclosed |
| US-20010027251-A1 | Phosphorothioate oligonucleotides having modified internucleoside linkages | ISIS PHARMACEUTICALS, INC. | 2001-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105311-A1 | Oligonucleotides having A-DNA form and B-DNA form conformational geometry | RNGTT, RNASEH1, ADAR | KDM4E 3583/4885TAS1R3 3873/4885TAS1R1 4114/4885 |
| US-20070292875-A1 | Human RNase H1 oligonucleotide compositions thereof | RNASEH1, RNASE1, RNASEL | KDM4E 4340/4885TAS1R3 4452/4885TAS1R1 4469/4885 |
| US-20030096979-A1 | Oligonucleotides having A-DNA form and B-DNA form conformational geometry | RNGTT, RNASEH1, ADAR | KDM4E 3583/4885TAS1R3 3873/4885TAS1R1 4114/4885 |
| US-20040102618-A1 | Human RNase H1 and oligonucleotide compositions thereof | RNASEH1, RNASE1, RNASEL | KDM4E 4275/4885TAS1R3 4453/4885TAS1R1 4454/4885 |
| US-20070123702-A1 | Oligonucleotdies having A-DNA form and B-DNA form conformational geometry | RNASEH1, RNGTT, ADAR | KDM4E 2494/4885TAS1R3 4377/4885TAS1R1 4530/4885 |
| US-20010027251-A1 | Phosphorothioate oligonucleotides having modified internucleoside linkages | TYMP, DTYMK, RNGTT | KDM4E 4113/4885TAS1R3 3455/4885TAS1R1 4007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.